Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis

Pharmacology & Therapeutics
Z ChenS J Chen

Abstract

Acute promyelocytic leukemia (APL) accounts for about 10% of all acute myeloid leukemias and is characterized by the chromosomal translocation t(15;17), which fuses the retinoic acid receptor (RAR) alpha gene to the promyelocytic leukemia (PML) gene. The PML-RAR alpha fusion gene plays an important role in leukemogenesis through antagonizing retinoic acid signalling and the regulatory pathways mediated by PML. APL is the first example of a human cancer that can be effectively treated with the differentiation inducer all-trans retinoic acid (ATRA). The therapeutic effect of ATRA in APL has been associated with the direct modulation of PML-RAR alpha, the restoration of the differentiation pathways regulated by wild-type RAR/retinoid X receptor heterodimer and PML. More recently, a second drug, arsenic trioxide (As2O3), has been discovered in China that also has a strong therapeutic effect against APL. As2O3 can induce clinical remission in de novo or relapsed APL patients and has no cross-resistance with ATRA. It has dual effects on APL cells: preferential apoptosis at high concentration (0.5-2 microM) and partial differentiation at low concentration (0.1-0.5 microM). Modulation and degradation of PML-RAR alpha proteins can be in...Continue Reading

References

Oct 1, 1992·Trends in Biochemical Sciences·M LeidP Chambon
Oct 1, 1995·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·K B Michels
Apr 1, 1994·Genes, Chromosomes & Cancer·J BorrowF Mitelman
Mar 14, 1995·Proceedings of the National Academy of Sciences of the United States of America·M CookS Gluecksohn-Waelsch
Aug 30, 1994·Proceedings of the National Academy of Sciences of the United States of America·S RuchaudM Lanotte
Jul 15, 1994·Genes & Development·V J Bardwell, R Treisman
May 1, 1994·Leukemia & Lymphoma·J H LiuK S Chang
Jul 15, 1993·The New England Journal of Medicine·R P WarrellL Degos
Jun 11, 1996·Proceedings of the National Academy of Sciences of the United States of America·M MaoZ Chen
Apr 15, 1997·Proceedings of the National Academy of Sciences of the United States of America·J ZhuH de Thé
Mar 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·D BrownJ M Bishop

❮ Previous
Next ❯

Citations

Feb 23, 2007·Science in China. Series C, Life Sciences·Jin ZhouBaofeng Yang
Nov 23, 2000·Toxicology Letters·Y RuanR L Vorce
Oct 16, 2001·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·M A AltinozA Sav
Jan 1, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T C ZhangJ F Qin
Mar 30, 2002·Critical Reviews in Oncology/hematology·Ann M Bode, Zigang Dong
Jun 9, 2012·International Journal of Nanomedicine·Ye WangYi-Ping Hu
Apr 29, 1999·Proceedings of the National Academy of Sciences of the United States of America·M GhoshB P Rosen
Jan 27, 2016·Biological Trace Element Research·Muthuraman PanduranganDoo Hwan Kim
Mar 28, 2013·International Journal of Endocrinology·Monika Puzianowska-KuznickaJacek Polosak
Aug 22, 2009·Evidence-based Complementary and Alternative Medicine : ECAM·Jia-Wei HsuHsueh-Fen Juan
Sep 23, 2000·Toxicology and Applied Pharmacology·K J TroubaR L Vorce
Sep 27, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean T BarbeySteven L Soignet
Oct 16, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hong-Hu ZhuXiao-Jun Huang
Sep 5, 2002·American Journal of Hematology·Vikram MathewsAlok Srivastava
May 30, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ahmad FatemiAhmad Kazemi
May 29, 2002·Oncogene·Jiang Zhu, Stephen G Emerson
Jan 19, 2005·Anti-cancer Drugs·Jiong HuZhu Chen
Oct 5, 2010·Environmental Toxicology·Tung-Yuan LaiJing-Gung Chung
Jun 29, 2018·Applied Biochemistry and Biotechnology·Tong ZhouLei Yang
Mar 28, 2019·Evidence-based Complementary and Alternative Medicine : ECAM·Wu-Ching UenCheng-Jeng Tai
May 19, 2021·Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society·Jonathan S FuerstLanning B Kline

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Proceedings of the National Academy of Sciences of the United States of America
J ZhuHugues de Thé
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Hio Chung KangJae-Gahb Park
Toxicology International
Pushpalatha ChinnamLeena M Shafee
Toxicological Sciences : an Official Journal of the Society of Toxicology
K J TroubaR L Vorce
© 2022 Meta ULC. All rights reserved